← Eichor
Study identifier: NCT06977711 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

Condition: Diffuse Large B-cell Lymphoma  ·  Sponsor: The University of Texas Health Science Center at San Antonio

PhasePhase 1
Planned participants10
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study is developed by the investigator and is a, phase I, single arm, clinical trial that will enroll subjects with untreated diffuse large B-cell lymphoma (DLCBL) at high risk for poor outcome. The types of treatments given will be shared with participants. The aims are: 1. To assess the safety and how well the participants tolerate the treatment 2. Assess the response of the tumor to treatment to estimate complete response 3. Assess the response of the tumor to treatment to estimate progression-free survival

This description comes directly from the study's public registry record.

Talk to the study team

Adolfo Diaz Duque, MD  ·  210-450-5904  ·  diazduque@uthscsa.edu

Ricardo E Aguiar, MD  ·  210-567-4860  ·  aguiarr@uthscsa.edu

Always discuss trial participation with your own doctor first.

Locations (2)

University Hospital SystemSan Antonio, Texas, United StatesRecruiting
University of Texas Health Science Center San Antonio at the Cancer Therapy and Research CenterSan Antonio, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06977711